|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM360582354 |
| 003 |
DE-627 |
| 005 |
20231226083321.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||jpn c |
| 024 |
7 |
|
|a 10.14989/ActaUrolJap_69_7_189
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1201.xml
|
| 035 |
|
|
|a (DE-627)NLM360582354
|
| 035 |
|
|
|a (NLM)37558640
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Doi, Keisuke
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Case of BRCA2 Mutation-Positive Intraductal Carcinoma of the Prostate
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.08.2023
|
| 500 |
|
|
|a Date Revised 11.08.2023
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A 75-year-old man presented with macroscopic hematuria and a high serum prostate-specific antigen (PSA) level. Macroscopic hematuria had subsided by the time of consultation. The PSA level was 38.590 ng/ml, which, along with rectal examination and magnetic resonance imaging findings, led to the suspicion of prostate cancer. Transrectal needle biopsy of the prostate revealed intraductal carcinoma of the prostate (IDC-P). Computed tomography and bone scintigraphy were performed, and the prostate cancer was classified as cT2cN0M0. After 6 months of combined androgen blockade therapy, a radical prostatectomy was performed; however, PSA levels continued to increase, and the patient was diagnosed with castration resistant prostate cancer. Multiple bone metastases appeared 5 months after the initiation of abiraterone therapy. Three courses of docetaxel and two courses of cabazitaxel were administered, but the disease progression continued. The IDC-P was found to be positive for the BRCA2 mutation by BRACAnalysis® performed at the start of cabazitaxel therapy. To our knowledge, no other cases of BRCA2 mutation positive IDC-P have been reported in Japan. After we started administration of Olaparib, the patient's PSA level was lowered and the disease progression stopped
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a cabazitaxel
|2 NLM
|
| 650 |
|
7 |
|a 51F690397J
|2 NLM
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 650 |
|
7 |
|a BRCA2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a BRCA2 Protein
|2 NLM
|
| 700 |
1 |
|
|a Fujii, Takanori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hanamoto, Masanori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takamura, Kousuke
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakada, Tetsuya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sato, Yumiko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ogura, Kazuma
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 69(2023), 7 vom: 09. Juli, Seite 189-192
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:69
|g year:2023
|g number:7
|g day:09
|g month:07
|g pages:189-192
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.14989/ActaUrolJap_69_7_189
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 69
|j 2023
|e 7
|b 09
|c 07
|h 189-192
|